Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys

Movement Disorders

Volumn 13, Issue 4, 1998, Pages 637-642

  Schneider, Jay S ^a   Pope Coleman, Anne ^a   Van Velson, Maria ^a   Menzaghi, Frederique ^b   Lloyd, G Kenneth ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

L dopa; Monkeys; NAChR; Parkinsonism

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; ANTIPARKINSON AGENT; LEVODOPA; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISABILITY; INTRAMUSCULAR DRUG ADMINISTRATION; LOCOMOTION; LONG TERM EXPOSURE; MALE; MONKEY; MOTOR ACTIVITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; SYMPTOM; VOMITING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; LEVODOPA; MACACA FASCICULARIS; MALE; MOTOR SKILLS; NEUROLOGIC EXAMINATION; NICOTINIC AGONISTS; PARKINSON DISEASE, SECONDARY; PYRIDINES; PYRROLIDINES; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC;

EID: 0031826455     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130405     Document Type: Article

References (20)

1. Baron JA. Cigarette smoking and Parkinson's disease. Neurology 1986;36:1490-1496.
2. Morens DM, Grandinetti A, Reed D, et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1051.
3. Janson AM, Fuxe K, Agnati LF, et al. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cells bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res 1988;455:332-345.
4. Sershen H, Hashim A, Wiener HL, Lajtha A. Effects of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse. Neurosci Lett 1988;93:270-274.
5. Owman CH, Fuxe K, Janson AM, Kahrstrom J. Chronic nicotine treatment eliminates asymmetry in striatal glucose utilization following unilateral transection of the mesostriatal dopamine pathway in rats. Neurosci Lett 1989;102:279-283.
6. Shahi GS, Moochhala SM, Das NP. The association between smoking and Parkinson's disease: new insights from studies using the mouse MPTP model. Eur J Pharmacol 1990;183:1100-1101.
7. Carr LA, Basham JK, York BK, Rowell PP. Inhibition of uptake of 1-methyl-4-phenylpyridinium ion and dopamine in striatal synaptosomes by tobacco smoke components. Eur J Pharmacol 1992;215:285-287.
8. Perry TL, Hansen S, Jones K. Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neurosci Lett 1987;74:217-220.
9. Fung YK, Fiske LA, Yuen-Sum L. Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice. Gen Pharmacol 1991;22:669-672.
10. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672.
11. Moll H. The treatment of post-encephalitic parkinsonism by nicotine. BMJ 1926;1:1079-1081.
12. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 1994;116:117-119.
13. Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci 1993;117:28-32.
14. Clemens P, Baron JA, Coffey D, Reeves A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology 1995;117:253-256.
15. Rowell PP, Carr LA, Garner AC. Stimulation of [3H]dopamine release by nicotine in rat nucleus accumbens. J Neurochem 1987;49:1449-1454.
16. Rowell PP. Nanomolar concentrations of nicotine increase the release of [3H]dopamine from rat striatal synaptosomes. Neurosci Lett 1995;189:171-175.
17. Mifsud J-C, Hernandez L, Hoebel BG. Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res 1989;478:365-367.
18. Sacaan AI, Reid RT, Santori EM, et al. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. J Pharmacol Exp Ther 1997;280:373-383.
19. Menzaghi F, Whelan KT, Risbrough VB, et al. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J Pharmacol Exp Ther 1997a;280:384-392.
20. Menzaghi F, Whelan KT, Risbrough VB, et al. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-dopa in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther 1997b;280:393-401.